Murine and HIV-Based Retroviral Vectors for In Vitro and In Vivo Gene Transfer
The success of experimental gene therapy is dependent on the ability to safely and efficiently introduce transgenes into the target cell or tissue. Retroviral-based vectors, notably those derived from Moloney murine leukemia virus (MLV) and lentiviral vectors derived from HIV, have proven to be valuable gene transfer vehicles as a result of their ease of production and their ability to mediate long-term transgene expression. One of the most widely used methods for viral vector production is based on the transient transfection of viral vector plasmid DNA into a producer cell line. Here, we describe protocols to produce and standardize high quality MLV-based retroviral and HIV-based lentiviral vectors for ex vivo and in vivo gene delivery.
Key WordsGene therapy lentivirus retrovirus HIV virus producer cells
- 15.Palmer, T. D. and Gage, F. H. (1996) Delivery of gene products to the central nervous system by grafting retrovirally engineered neuronal and nonneuronal cells, in Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders, (Lowenstein, P. R. and Enquist, L.W., eds.). John Wiley and Sons Ltd, New York pp. 235–262.Google Scholar
- 25.Chen, S. T., Iida, A., Guo, L., Friedmann, T., and Yee, J. K. (1996) Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc. Natl. Acad. Sci. USA 93, 10,057–10,062.CrossRefPubMedGoogle Scholar
- 26.Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J. K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033–8037.CrossRefPubMedGoogle Scholar